Nanjing Leading Medical Technology Co., Ltd.

Home page

Renew yourself daily, and keep renewing day after day! Leading Medical has secured another invention patent, with innovation never ceasing.

Good news keeps pouring in, and innovation never stops! Leading Medical has once again achieved a major technological breakthrough— “A D-dimer monoclonal antibody and its applications” The invention patent has been officially approved—this is a significant achievement for Liding. Invention Patent No. 33 , marking the company’s Thrombotic Disease Testing Field Achieve new breakthroughs in core technologies, driven by the power of innovation. Innovation empowers precise thrombosis detection!

Establish a robust core reagent system, enabling… “Technological Innovation” Driving development; this antibody can be widely applied in Latex immunoturbidimetry, immunochromatography Through the preparation of a variety of reagents, we are further refining our portfolio of core in vitro diagnostic reagents, injecting new momentum into the industry’s technological upgrade.

Avoid “one-off breakthroughs” and build a “continuously iterative innovation chain.”

Rather than pursuing “one-off breakthroughs,” we are building a “continuously iterative innovation chain.” On the fast‑evolving trajectory of in vitro diagnostic technologies, Leading has always firmly believed that, A single technological breakthrough is unlikely to sustain long-term core competitiveness; only by embedding innovation into the very fabric of development and establishing a closed-loop, iterative system of “R&D–breakthrough–commercialization–re‑R&D” can we maintain industry leadership.

From the precision development of HbA1c monoclonal antibodies to the technological breakthroughs in D-dimer monoclonal antibodies, each patented achievement is not the end of innovation but rather the starting point for the next wave of technological advancement. This iterative approach to innovation not only enables each technological breakthrough to be swiftly translated into high‑quality, clinically applicable reagents, but also continuously strengthens our technological moats, sustaining a steady stream of innovative momentum and providing sustained impetus for the high‑quality development of the in vitro diagnostics industry.

Leading Biochemical Immunoassay Reagents—Cardiovascular Testing Series

Test Items	English abbreviation	Reagent ratio	Item number	Detection method
D-dimer	D-Dimer	R1:R2=3:1	LD-DD-03	Latex-enhanced immunoturbidimetric assay
Angiotensin-converting enzyme	ACE	R:S=8:1	LD-ACE-01	Rate method
Lipoprotein-associated phospholipase A2	Lp-PLA2	R1:R2=4:1	LD-Lp-PLA2-02	Latex-enhanced immunoturbidimetric assay
Sialic acid	South Africa	R1:R2=3:1	LD-SA-01	Rate method
Antithrombin III	ATIII	R1:R2=4:1	LD-ATIII-01	Immunoturbidimetric assay
Superoxide dismutase	SOD	R1:R2=3:1	LD-SOD-01	Colorimetric method
Non-esterified fatty acids	NEFA	R1:R2=4:1	LD-NEFA-01	Enzymatic method
Myeloperoxidase	MPO	R1:R2=3:1	LD-MPO-01	Latex-enhanced immunoturbidimetric assay